Intravesical Ozone Therapy for Interstitial Cystitis/Bladder Pain Syndrome

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorMedipol University

About this trial

This randomized, double-blind, placebo-controlled trial evaluated the efficacy and safety of intravesical ozone therapy in 60 patients with interstitial cystitis (IC). Participants were assigned to ozone therapy, placebo, or standard care groups for 3 weeks, with follow-up at 6 weeks. The primary outcome was the change in O'Leary-Sant ICSI score. Secondary outcomes included VAS pain score, SF-36 physical health, and urinary frequency.

Eligibility criteria

Qualifiers

Age 18-65 years

Histopathologically or clinically confirmed IC (per AUA guidelines)

Symptoms for at least 6 months

Willing to provide informed consent

Disqualifiers

Active urinary tract infection

Bladder malignancy

Pregnancy or breastfeeding

Known ozone allergy

Trial design

Treatments tested in this trial

  • Intravesical Ozone Therapy
  • Placebo (Normal Saline)
  • Control

Treatment groups

60 Participants
are divided into 3 treatment groups

Sponsors and collaborators